Confirmed objective response rate (ORR) of 15.6% in all patients regardless of PD-L1 or HPV status Confirmed ORR of 17.4% in subset of patients with PD-L1+ disease Confirmed ORR of 22.2% in subset of patients with HPV+ disease Median duration of treatment in responders was 19.6 months at the time of data cutoff SOUTH SAN FRANCISCO, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a... Read More